On Friday, the US Food and Medicine Administration expanded its clearance for the use of an anti-viral drug, called remdesivir, which was developed by the Gilead Sciences, to include non-hospitalized children aged 12 and up with mild-to-moderate COVID-19 disease and a high risk of hospitalisation.
Veklury was formerly only used in individuals who needed to be admitted to the hospital.
Post Your Comments